The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 236.00
Bid: 232.00
Ask: 240.00
Change: 0.00 (0.00%)
Spread: 8.00 (3.448%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 236.00
ANCR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update, revised date for full year results

25 Mar 2020 07:00

RNS Number : 4809H
Animalcare Group PLC
25 March 2020
 

25 March 2020

 

 

Animalcare Group plc

(the "Group" or the "Company")

 

Trading update and revised date for full year results

 

25 March 2020. Animalcare Group plc (AIM: ANCR), the international animal health business, today announces that it has deferred publication of its 2019 final results, originally scheduled for 31 March 2020.

This deferral follows the FCA's request for all listed companies to delay release of upcoming preliminary results in light of the COVID-19 crisis. As an AIM company the decision was made in consultation with our advisers, including the Group's auditors.

We will advise shareholders of the revised publication date of the audited full year results for the year to 31 December 2019 in due course.

Current trading

The Group entered 2020 in a strong financial position. The Company's most recent trading update for the 2019 financial year, issued on 23 January 2020, showed significant improvements against key performance indicators such as net debt and cash conversion while earnings were in line with expectations. At 29 February 2020, both net debt and the net-debt-to-underlying-EBITDA leverage ratio were at similar levels to 31 December 2019.

Despite the macro uncertainty caused by the pandemic, the Group has been trading in line with market expectations since the start of the financial year. However, feedback from our customers and supply chain partners indicates that some level of disruption to our operations is unavoidable. For example, many veterinary practices in our core markets that treat companion animals are now handling emergency cases only. The production animal sector, which accounts for around 25% of our revenues, appears to be less affected.

Financial strength

Maintaining our financial strength is key, both in terms of the Group's resilience and, importantly, its ability to focus on the execution of its growth strategy. Notwithstanding the acute challenges posed by COVID-19, the Board believes that the Group will continue to be well placed to take advantage of opportunities in a market with attractive fundamentals.

The Company is implementing a range of measures to preserve cash and reduce overheads including deferrals of non-essential capital projects across the Group.

The Board has taken the decision to defer the payment of the final dividend with the aim of providing a platform to continue progressing opportunities during the current crisis. The decision will be reviewed later in the year once we have more clarity about the ongoing effects of the pandemic on our business. At that point the Board will consider what actions are in the best interests of shareholders. This could result in the payment of a second dividend for the year ended 31 December 2019, or the retention of cash in the business to invest in future growth opportunities. Following this suspension, the Company will retain an additional approximately £1.4 million in cash.

Guiding us at all times is our primary responsibility to ensure the health, safety and wellbeing of our people. Consistent with this principle, we are adhering to the guidelines issued by relevant authorities on measures such as home working and social distancing.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

For further information, please contact:

 

Animalcare Group plc

Jenny Winter, Chief Executive Officer

Chris Brewster, Chief Financial Officer

 

Tel: 01904 487 687

Panmure Gordon(Nominated Adviser & Broker)

Corporate Finance

Freddy Crossley/Emma Earl

Corporate Broking

James Stearns

Tel: 020 7886 2500

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTJAMMTMTBTMJM
Date   Source Headline
12th Jul 202111:04 amRNSNotification of Major Holding
12th Jul 20217:00 amRNSExercise of options
9th Jul 20214:59 pmRNSNotification of Major Holding
9th Jul 20213:20 pmRNSNotification of Major Holding
8th Jul 20215:45 pmRNSResult of Secondary Placing
8th Jul 20214:41 pmRNSSecond Price Monitoring Extn
8th Jul 20214:35 pmRNSPrice Monitoring Extension
8th Jul 20212:06 pmRNSSecond Price Monitoring Extn
8th Jul 20212:00 pmRNSPrice Monitoring Extension
8th Jul 20211:00 pmRNSProposed Secondary Placing
1st Jul 20217:00 amRNSTotal Voting Rights
21st Jun 20217:00 amRNSExercise of options
17th Jun 202110:17 amRNSDirector/PDMR Notification
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20215:03 pmRNSResult of 2021 AGM
17th May 20217:00 amRNSAnnual Report 2020 and Notice of AGM
22nd Apr 20217:00 amRNSDaxocox approved by EU and UK authorities
30th Mar 20217:00 amRNSFull Year Results 2020
23rd Mar 20217:00 amRNSNotification of major holding
18th Feb 20214:36 pmRNSPrice Monitoring Extension
18th Feb 20213:43 pmRNSDaxocox receives positive opinion from CVMP in EU
8th Feb 20212:46 pmRNSNotification of major holding
1st Feb 20217:00 amRNSAppointment of Nominated Advisor and Joint Broker
21st Jan 20217:00 amRNSTrading Update and Notice of Full Year Results
18th Nov 20207:00 amRNSGrant of options
29th Sep 20207:00 amRNSInterim Results H1 2020
28th Sep 20207:00 amRNSAnimalcare and Kane Biotech to target biofilms
23rd Jul 20207:00 amRNSTrading Update and Notice of Results
30th Jun 20204:00 pmRNSResult of AGM 2020
9th Jun 20203:55 pmRNS2019 Annual Report and Notice of 2020 AGM
28th May 20207:00 amRNSFull year results 2019
18th May 202011:20 amRNSNotice of Full Year 2019 Results
25th Mar 20207:00 amRNSTrading update, revised date for full year results
23rd Jan 20207:00 amRNSTrading Update & Notice of Results
17th Jan 20208:55 amRNSHoldings in Company
24th Sep 20197:00 amRNSHalf Year Results
25th Jul 20197:00 amRNSDirectorate Change
23rd Jul 20197:00 amRNSTrading Update & Notice of Results
16th Jul 201911:37 amRNSNotification of major holdings
25th Jun 20191:40 pmRNSResult of AGM
19th Jun 20193:52 pmRNSBoard change
10th Jun 20192:55 pmRNSDirector/PDMR Shareholding
22nd May 20197:00 amRNSAnnual Report and Notice of Annual General Meeting
8th May 201910:35 amRNSDividend Declaration
30th Apr 20197:00 amRNS2018 Full Year Results
21st Jan 20197:00 amRNSTrading Update and Notice of Results
30th Oct 20187:50 amRNSAdditional Listing
1st Oct 201812:45 pmRNSAdditional Listing
25th Sep 20185:36 pmRNSDividend Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.